ImmunoGen, Inc. Common Stock Quote & Summary Data
Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Symbol Lookup |
|
CLOSEX
Investing just got easier…Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now |
Key Stock Data
Intraday Chart
Trading Range
The current last sale of $10.545
| Intraday | Last 52 Weeks | |
| High: | $ 10.66 | $ 10.04 |
| Low: | $ 8.9701 | $ 2.31 |
Company Description (as filed with the SEC)
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using our proprietary antibody-drug conjugate, or ADC, technology. An ADC with our technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of our potent anti-cancer agents as a "payload" to kill the tumor cell once the ADC has bound to its target. ADCs are an expanding approach to the treatment of cancer, with two approved products and the number of agents in development more than doubling during the last five years. We have established a leadership position in ADCs. Our technology is deployed in Roche's Kadcyla® (ado-trastuzumab emtansine), the first ADC to demonstrate superiority over standard of care in a randomized pivotal trial, EMILIA, and gain FDA approval. ... More ...
Nasdaq Official Price
|
Open Price:
$ 9.16 |
Open Date:
Feb. 12, 2018 |
|
|
Close Price:
$ 10.545 |
Close Date:
Feb. 12, 2018 |
